News

The approval is conditional solely upon a minor change to the informed consent form that has already been submitted to the FDA. Full approval of the amendment is

Oliceridine is being developed as a potential replacement for currently approved intravenous opioid analgesics. In a recently completed Phase 2 study in postoperative pain, oliceridine matched the analgesic

The program has been initiated today and will be made available to eligible patients in the U.S. and selected European countries diagnosed with relapsed or refractory acute myeloid

The companies agreed to further develop Zymeworks’ Effector Function Enhancement and Control Technology (EFECT) platform by designing, engineering, and testing new engineered Fc domains with specific antibody-mediated immune

It is hoping that the therapy derived from human placenta cell can protect people from radiation exposure, especially those involved in nuclear plant decommissioning. The partnership intends to

The study found that blood levels of two neurotoxic compounds dropped significantly in depressed patients after they were treated with the antidepressant escitalopram (Lexapro). The study, published in

The collaboration is focussed on developing future-generation utrophin modulators for the potential treatment of all patients with the progressive muscle wasting disorder Duchenne muscular dystrophy (DMD). The research

The Department of Oncology at Vejle Hospital, under the leadership of professor Anders Jakobsen and in corporation with Dr. Torben Frøstrup Hansen, has been identified by the collaborators

As a result Nucala is now approved for use in the 31 European countries covered by the European Medicines Agency (EMA). Nucala is the first and only approved